PROS1 and Cirrhosis: In November 2017, the clinical use of pan-genotypic, dual direct-acting antiviral agent (DAA) therapy using the non-structural protein (NS)3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir was approved in Japan for hepatitis C virus (HCV)-infected patients without cirrhosis or with compensated cirrhosis [1,2].